Evidence map›Paper›PMID 40394906›Full record

ArticleMicrocirculation (New York, N.Y. : 1994)2025

Oxidized Cell-Free Hemoglobin Induces Mitochondrial Dysfunction by Activation of the Mitochondrial Permeability Transition Pore in the Pulmonary Microvasculature.

Kyle J Riedmann, Jamie E Meegan, Aqeela Afzal, Yatzil Cervantes-Cruz, Sarah Obeidalla, Avery M Bogart, Lorraine B Ware, Ciara M Shaver, Julie A Bastarache

Abstract read
In one paragraph

Article in Microcirculation (New York, N.Y. : 1994), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kyle J RiedmannDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0002-8708-8687
Jamie E MeeganDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-2644-676X
Aqeela AfzalDepartment of Neurosurgery, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Yatzil Cervantes-CruzDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Sarah ObeidallaDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Avery M BogartDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0002-3912-3177
Lorraine B WareDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-9429-4702
Ciara M ShaverDivision of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-5677-0288
Julie A BastaracheDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, Tennessee, USA.ORCID 0000-0003-0458-6507

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Applying Innovative Lung Mapping Strategies to Understand Alveolar Capillary Barrier Permeability in ARDSR35HL150783 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Julie A. Bastarache · 2020 to 2026
$4.6M
Neuroinflammatory mechanisms underlying sepsis-induced cognitive dysfunctionRF1AG075341 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BASTARACHE, JULIE A., HARRISON, FIONA EDITH · 2022 to 2025
$3.3M
Haptoglobin 2 variant and endothelial glycocalyx shedding in sepsis-induced ARDSR01HL158906 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WARE, LORRAINE B · 2021 to 2024
$2.3M
The Sepsis ClinicAl Resource And Biorepository (SCARAB) ProjectR33GM144915 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BASTARACHE, JULIE A., WARE, LORRAINE B · 2024 to 2025
$1.5M
Conventional 200 keV Transmission Electron MicroscopeS10OD034315 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JEROME, WALTER G · 2023 to 2023
$597k
NCI NIH HHS P30 CA068485NCRR NIH HHS S10 RR027396NEI NIH HHS P30 EY008126NHLBI NIH HHS F30 HL170483NHLBI NIH HHS F31 HL167471NHLBI NIH HHS R01 HL158906NHLBI NIH HHS R35 HL150783NIA NIH HHS RF1 AG075341NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIGMS NIH HHS R33 GM144915NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284NIH HHS R24 OD037694NIH HHS S10 OD034315
6 · The paper itself

Abstract

objectiveCell-free hemoglobin (CFH) is released into the circulation during sepsis where it can redox cycle from the ferrous 2+ to ferric 3+ and disrupt endothelial function, but the mechanisms of CF-mediated endothelial dysfunction are unknown. We hypothesized that oxidized CFH induces mitochondrial dysfunction via the mitochondrial permeability transition pore (mPTP) in pulmonary endothelial cells, leading to the release of mitochondrial DNA (mtDNA).

methodsHuman lung microvascular endothelial cells were treated with CFH2+/CFH3+. We measured mitochondrial mPTP activation (flow cytometry), network and mass (immunostaining), structure (electron microscopy), mtDNA release (PCR), and oxygen consumption rate (OCR; Seahorse). Plasma from critically ill patients and conditioned cell media were quantified for mtDNA and CFH.

resultsCFH3+ disrupted the mitochondrial network, activated the mPTP (1434 (874-1642) vs. 2302 (1729-2654) mean fluorescent intensity, p = 0.02), increased the spare respiratory capacity (30.61 (29.36-37.78) vs. 7.83 (3.715-10.63) OCR, p = 0.004), and caused the release of mtDNA. CFH was associated with circulating mtDNA (R

conclusionCFH3+, not CFH2+, is the primary driver of CFH-induced lung microvascular mitochondrial dysfunction. Activation of the mPTP and the release of mtDNA are a feature of CFH3+ mediated injury.

Indexed as

Endothelial CellsHemoglobinsLungMicrovesselsMitochondriaMitochondrial Membrane Transport ProteinsAgedDNA, MitochondrialFemaleHumansMaleMiddle AgedMitochondrial Permeability Transition PoreOxidation-ReductionDNA, MitochondrialHemoglobinsMitochondrial Membrane Transport ProteinsMitochondrial Permeability Transition Porecell‐free hemoglobinmitochondrial dysfunctionmitochondrial permeability transition poremtDNA

Identifiers

PMID40394906
PMCPMC12093041

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.